Abre Venous Self-Expanding Stent System
Medtronic Vascular, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA database entry P200026/S019 records a 30-Day Notice for the Abre™ Venous Self-Expanding Stent System, filed by Medtronic Vascular, Inc. under product code QAN. The supplement type is listed as a process change involving manufacturer, sterilizer, packager, or supplier. The stated purpose is a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices. It does not describe a change to the stent itself, its design, or its labeled use.
The PMA number links this notice to the original Abre approval, but it is a supplement, not a new approval of the whole system. The entry reports a manufacturing-process purpose; it does not present independent evidence of safety, sterility assurance, or clinical effectiveness. The supplied statement leaves the previous and new incubation times absent, along with the specific biological indicator and the validation supporting the change. The decision field reads OK30, and no decision detail beyond that label is provided.
FDA approval order statement
approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200026/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, iliac vein.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200026 · Original PMA
Abre Venous Self-expanding Stent System
P200026/S019 received
Application receipt date recorded by FDA.
P200026/S019 · FDA decision
30-Day Notice
P200026/S020 · Related supplement
Abre Venous Self-expanding Stent System
Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA approval | Oct 21, 2020 | FDA | |
Abre Venous Self-expanding Stent SystemP200026/S020 | Medtronic Vascular, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P200026/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
